Anxiety disorders are the most common form of mental disorders in the United States, affecting nearly 40 million American adults and more efficacious pharmacological treatments are needed. This project, to be conducted at Boston University in the rich neuroscience community of Boston, concerns the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP), a member of the secretin/glucagon/VIP superfamily, and a pleiotropic molecule with remarkable central actions on neuroendocrine and behavioral systems. Although the interest towards this fascinating polypeptide continues to increase exponentially, the role of this neuropeptide in the modulation of stress response and its function in the extended amygdala, a key brain site for the behavioral manifestations of stress, are yet to be elucidated. Continued existence of this gap represents an obstacle to the potential benefits that can derive by understanding the role of PACAP in stress and anxiety disorders. Our preliminary data suggest a role for PACAP in the modulation of behavioral response to stress, which seems to be mediated by the receptors of the major brain stress peptide, corticotropin-releasing factor (CRF). Our long-term goal is therefore to elucidate the role of neuropeptide systems in the neurobiology of stress- related disorders. The objective of this application is to understand how the PACAP system is involved in the behavioral response to stress, with the long-term goal to provide novel therapeutic strategies for the management of stress and anxiety disorders. The central hypothesis under test in this proposal is that the endogenous PACAP system in the extended amygdala is recruited following exposure to stress and that PAC1 receptor antagonists exert an anxiolytic-like action. A sub-hypothesis is that the anxiogenic effects of PACAP are mediated by the recruitment of the extra-hypothalamic CRF system. This hypothesis will be tested by pursuing three specific aims;the brain sites important for the anxiogenic effects of PACAP will be characterized in Specific Aim 1, using intracranial microinjection of PACAP-38. The role of endogenous brain PACAP system in anxiety-like behavior will be explored in Specific Aim 2, through the investigation of the potential anxiolytic effect of a PAC1 antagonist and of the effects of stressors on PACAP and PAC1 receptor levels in discrete brain regions. Finally Specific Aim 3 will investigate the role of hypothalamic and extrahypothalamic CRF in the effects of PACAP using a pharmacological and molecular approach. The results of the proposed experiments, through this multidisciplinary approach, will provide novel insights into this neuropeptide system as a mechanism for modulating anxiety-like behavior, and may ultimately lead to the a new class of therapeutic agents for the treatment of anxiety-like disorders.

Public Health Relevance

The results of the present studies, providing key information regarding the role of the neuropeptide PACAP in stress and anxiety, will define specific mechanisms underlying anxiety disorders, and may provide novel therapeutic strategies for stress-related disorders and anxiety.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Neuroendocrinology, Neuroimmunology, Rhythms and Sleep Study Section (NNRS)
Program Officer
Desmond, Nancy L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Boston University
Schools of Medicine
United States
Zip Code
Ferragud, Antonio; Howell, Adam D; Moore, Catherine F et al. (2017) The Trace Amine-Associated Receptor 1 Agonist RO5256390 Blocks Compulsive, Binge-like Eating in Rats. Neuropsychopharmacology 42:1458-1470
Moore, Catherine F; Schlain, Gabrielle S; Mancino, Samantha et al. (2017) A behavioral and pharmacological characterization of palatable diet alternation in mice. Pharmacol Biochem Behav 163:1-8
Moore, Catherine F; Sabino, Valentina; Koob, George F et al. (2017) Neuroscience of Compulsive Eating Behavior. Front Neurosci 11:469
Vilgis, Veronika (2017) Can Affective Neuroscience Predict Who Will Develop Depression? Biol Psychiatry Cogn Neurosci Neuroimaging 2:7-8
Iemolo, Attilio; Seiglie, Mariel; Blasio, Angelo et al. (2016) Pituitary adenylate cyclase-activating polypeptide (PACAP) in the central nucleus of the amygdala induces anxiety via melanocortin receptors. Psychopharmacology (Berl) 233:3269-77
Valenza, Marta; DiLeo, Alyssa; Steardo, Luca et al. (2016) Ethanol-related behaviors in mice lacking the sigma-1 receptor. Behav Brain Res 297:196-203
Seiglie, Mariel P; Smith, Karen L; Blasio, Angelo et al. (2015) Pituitary adenylate cyclase-activating polypeptide induces a depressive-like phenotype in rats. Psychopharmacology (Berl) 232:3821-31
Iemolo, Attilio; Ferragud, Antonio; Cottone, Pietro et al. (2015) Pituitary Adenylate Cyclase-Activating Peptide in the Central Amygdala Causes Anorexia and Body Weight Loss via the Melanocortin and the TrkB Systems. Neuropsychopharmacology 40:1846-55
Blasio, Angelo; Valenza, Marta; Iyer, Malliga R et al. (2015) Sigma-1 receptor mediates acquisition of alcohol drinking and seeking behavior in alcohol-preferring rats. Behav Brain Res 287:315-22
Smith, Karen L; Rao, Rahul R; Velázquez-Sánchez, Clara et al. (2015) The uncompetitive N-methyl-D-aspartate antagonist memantine reduces binge-like eating, food-seeking behavior, and compulsive eating: role of the nucleus accumbens shell. Neuropsychopharmacology 40:1163-71

Showing the most recent 10 out of 25 publications